Want to see NVNO full AI Analyst Report?
Top Page
enVVeno Medical
(NASDAQ:NVNO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$10.50
▲(1.06% Upside)
Action:Reiterated
Date:07/31/26
The score is primarily constrained by weak financial performance (pre-revenue status, persistent losses, and ongoing cash burn implying continued external funding needs), partially offset by low leverage. Technicals are neutral-to-weak with the stock below its 200-day average, and valuation signals are limited due to a negative P/E and no dividend yield data.
Positive Factors
Regulatory progress: pivotal study approval
FDA/pivotal study approval to initiate the TAVVE pivotal study materially de-risks the regulatory pathway. Starting a pivotal trial enables generation of pivotal clinical evidence needed for regulatory filings, commercial reimbursement discussions, and partner interest over the next 2–6 months.
Negative Factors
Pre-revenue status
The company remains pre-revenue, meaning commercial cash inflows are absent until regulatory approval and market adoption occur. This structural lack of product revenue sustains dependence on external capital and prolongs the timeline to profitability and scalable margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: pivotal study approval
FDA/pivotal study approval to initiate the TAVVE pivotal study materially de-risks the regulatory pathway. Starting a pivotal trial enables generation of pivotal clinical evidence needed for regulatory filings, commercial reimbursement discussions, and partner interest over the next 2–6 months.
Read all positive factors
enVVeno Medical (NVNO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.24M
Dividend YieldN/A
Average Volume (3M)589.93K
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue GrowthN/A
EPS Growth43.06%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-520.08
Shares Outstanding682,722
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$30.00Price Target Upside188.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
enVVeno Medical Business Overview & Revenue Model
Company Description
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutio...
How the Company Makes Money
null...
enVVeno Medical Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -237.00K | 0.00 | -528.00K | -546.00K | -525.00K | -452.91K |
| EBITDA | -15.74M | -18.98M | -21.29M | -22.97M | -24.14M | -16.07M |
| Net Income | -15.72M | -19.47M | -21.82M | -23.52M | -24.67M | -16.53M |
Balance Sheet | ||||||
| Total Assets | 22.66M | 29.56M | 44.95M | 48.63M | 41.66M | 57.70M |
| Cash, Cash Equivalents and Short-Term Investments | 21.49M | 28.21M | 43.15M | 46.41M | 39.04M | 54.73M |
| Total Debt | 505.00K | 700.00K | 1.06M | 1.40M | 1.72M | 2.01M |
| Total Liabilities | 1.99M | 2.43M | 2.79M | 2.44M | 2.93M | 3.29M |
| Stockholders Equity | 20.67M | 27.13M | 42.16M | 46.20M | 38.73M | 54.40M |
Cash Flow | ||||||
| Free Cash Flow | -14.62M | -15.57M | -16.88M | -18.89M | -15.73M | -12.22M |
| Operating Cash Flow | -14.62M | -15.57M | -16.84M | -18.86M | -15.62M | -11.85M |
| Investing Cash Flow | 14.27M | 15.86M | 1.33M | -7.87M | -34.55M | -368.00K |
| Financing Cash Flow | 1.15M | 1.02M | 13.64M | 25.79M | 0.00 | 57.61M |
enVVeno Medical Risk Analysis
enVVeno Medical disclosed 36 risk factors in its most recent earnings report. enVVeno Medical reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The Company received a not-approvable letter from the FDA. Q4, 2025
enVVeno Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $7.24M | -0.01 | -66.39% | ― | ― | 43.06% | |
48 Neutral | $3.44M | -0.15 | -268.55% | ― | 39.98% | 90.08% | |
46 Neutral | $35.44M | -0.13 | -49.65% | ― | -95.74% | -118.94% | |
46 Neutral | $51.56M | -0.66 | 239.44% | ― | 10.38% | 20.70% | |
44 Neutral | $22.68M | -1.94 | -165.13% | ― | 7.72% | 34.39% | |
42 Neutral | $10.81M | -0.30 | -592.55% | ― | -59.95% | 56.67% |
* Healthcare Sector Average
NVNO
enVVeno Medical
11.15
-159.65
-93.47%
SINT
Sintx Technologies
1.66
-1.00
-37.59%
CTSO
Cytosorbents
0.38
-0.54
-58.80%
PAVM
PAVmed
5.04
-9.66
-65.71%
COCH
Envoy Medical
0.69
-0.79
-53.51%
TNON
Tenon Medical, Inc.
0.19
-1.21
-86.29%
enVVeno Medical Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
enVVeno Medical Updates Investors With New Presentation
Neutral
Jul 15, 2026
On July 14, 2026, enVVeno Medical Corporation released a new investor presentation intended for use in meetings with investors, analysts, and other stakeholders. The materials were furnished via a Form 8-K filing, explicitly designated as not R...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.